|Description||4-Phenyl-2-pyrrolidone-1-acetamide is a GABA derivative that exhibited apparent immunocorrection properties during immunosuppression induced by cyclophosphamide. It is used as a stimulant nootropic drug which can be up to 30-60 times more potent than piracetam. It may have anti-amnesic, antidepressant, anticonvulsant, antipsychotic, anxiolytic, and memory enhancement effects. It has been evaluated for its efficacy in reducing neurological deficits related to cerebral ischemia, epilepsy, and neurobehavioral disorders. At 10-100 mg/kg in mice, it can increase locomotor and antidepressant activity in the open-field and forced swimming tests, and can enhance memory in a passive avoidance response test. It was developed in 1983 in Russia. It has been listed as a banned substance by the World Anti-Doping Agency and the International Olympic Committee because of its cognitive enhancing and general stimulant properties. It is intended for research and forensic purposes only.|
|Quantity||Kilogram to ton|
|Quality Standard||In-house standard|
|Current Developer||It has been approved the listing.|
ZK200775 hydrate(Fanapanel; MPQX) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 &mu...
It is one of a series of AMPA modulators for the potential treatment of Alzheimer's disease, schizophrenia, and mild cognitive impairment (MCI). An ampakine dru...
CMPDA is a positive allosteric modulator of AMPA receptors. Binds at the modulator binding pocket located at the interdimer interface and the clamshell hinges.
A poliamine amide as potent Spermidine uptake inhibitor.
The (S)- but not (R)-isomers of willardiine and 5-bromowillardiine were potent agonists, producing rapidly but incompletely desensitizing responses. At a concen...
Tezampanel, a decahydroisoquinoline derivative, has been found to be AMPA receptor as well as Kainic acid receptor antagonist that could probably be useful in s...
Competitive AMPA/kainate antagonist. In rat cortical membranes, displays high affinity for [3H]-AMPA (Ki = 120 nM) and [3H]-CNQX (Ki = 32 nM) binding sites and ...
NS-1209, an AMPA/GluR5 receptor antagonist, is a antiepileptic drug candidate currently under clinical trials.
LY-326325, a decahydroisoquinaline derivative, has been found to be an AMPA receptor antagonist and was once studied for neuroprotection.
Naspm 3HCl is a potent and selective Ca2+ permeable AMPA receptor blocker.
EGIS-8332 potently decreased AMPA and quisqualate induced LDH release (IC50 = 5.2 ± 0.4 and 7.4 ± 1.3 μM, respectively) from the cells. The inhibition of the AM...
This active molecular is an AMPA receptor antagonist which blocks AMPA receptors in 10-20µM concentrations. It is also a Glutamate receptor antagonist. NBQX was...
LY 215490, a decahydroisoquinoline derivative, has been found to be an AMPA receptor antagonist that could be a neuroprotective agent in the study of focal isch...
4-Phenyl-2-pyrrolidone-1-acetamide is a GABA derivative that exhibited apparent immunocorrection properties during immunosuppression induced by cyclophosphamide...
GYKI-53784, a dioxolbenzene derivative, has been found to be a AMPA receptor antagonist that could block excitotoxicity and decrease auditory nerve activity at ...
Talampanel, also known as LY300164 and GYKI-53773, is a glutamate receptor inhibitor with anti-seizure activity. Talampanel is also an orally active, potent an...
GYKI-53405 is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA receptor) antagonist. It can bind to Xenopus brain membranes ...
LY3130481, a benzothiazol derivative, has been found to be the first AMPA receptor antagonist that could be probably effective in studies of epilepsy. It has ju...
(S)-(-)-5-Fluorowillardiine Hcl is a potent and specific AMPAR agonist.
A more potent and selective AMPA receptor agonist (at hGluR1 and hGluR2) than AMPA itself (Ki = 14.7, 25.1, and 1820 nM for hGluR1, hGluR2 and hGluR5 respective...